Business
Cardiol Therapeutics Commences Trading on the OTCQX
Oakville, Ontario--(Newsfile Corp. - May 30, 2019) - Cardiol Therapeutics Inc. ( TSX: CRDL) (O...
About this update from Cardiol Therapeutics Inc. Class A
[{"type":"text","content":"Cardiol Therapeutics Commences Trading on the OTCQXOakville, Ontario--(Newsfile Corp. - May 30, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (\"Cardiol\" or the \"Company\"), a leader in the research and commercial development of pharmaceutical CBD and targeted therapies for inflammatory diseases, is pleased to announce that it has qualified to trade on the OTCQX® Best Market and begins trading today under the symbol \"CRTPF\". U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the Company on www.otcmarkets.com.The OTCQX Best Market is for established, investor-focused U.S. and international companies. To qualify for the OTCQX market, companies must meet high financial standards, follow best practice corporate governance, demonstrate compliance with U.S. securities laws, be current in their disclosure, and have a professional third-party sponsor introduction. International companies must maintain a listing on a qualified foreign exchange or be an SEC reporting company and meet rigorous reporting standards. The companies found on OTCQX are distinguished by the integrity of their operations and the diligence with which they convey their qualifications. \"Trading on the OTCQX Best Market will assist us with increasing our U.S. shareholder base and investor awareness as we prepare to launch our ultra-pure pharmaceutical CBD products in the billion dollar markets in Canada, Latin America, and Europe and initiate ground-breaking international clinical trials in heart disease later this year,\" said David Elsley, President and CEO of Cardiol Therapeutics. Dorsey & Whitney LLP acted as the Company's OTCQX sponsor. About Cardiol TherapeuticsCardiol Therapeutics Inc. is a leader in the research and commercial development of pharmaceutical CBD products and targeted therapies for inflammatory disease. The Company is leveraging its expertise in pharmaceutical CBD to develop ultra-pure CBD products for commercialization in the billion dollar market for medicinal cannabinoids in Canada, with a view to expanding into Europe and Latin America, and nanotechnologies designed to deliver cannabinoids and other anti-inflammatory drugs for the treatment of heart failure. Heart failure is a leading cause of death and hospitalization, with associated healthcare costs exceeding $30 billion annua...